Empowered Funds LLC Makes New Investment in Envista Holdings Co. (NYSE:NVST)

Empowered Funds LLC purchased a new stake in Envista Holdings Co. (NYSE:NVST - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,366 shares of the company's stock, valued at approximately $374,000.

A number of other large investors have also recently modified their holdings of the business. Nuance Investments LLC increased its stake in Envista by 4.4% in the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company's stock valued at $145,168,000 after acquiring an additional 308,221 shares during the last quarter. Clarkston Capital Partners LLC increased its position in shares of Envista by 0.4% during the 3rd quarter. Clarkston Capital Partners LLC now owns 4,347,300 shares of the company's stock valued at $85,903,000 after purchasing an additional 17,085 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company's stock valued at $78,480,000 after buying an additional 830,861 shares in the last quarter. Pacer Advisors Inc. lifted its position in Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock worth $69,749,000 after buying an additional 642,401 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Envista by 2.5% in the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock worth $57,233,000 after buying an additional 71,435 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Mizuho started coverage on shares of Envista in a research note on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price target on the stock. Piper Sandler boosted their price target on shares of Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Wells Fargo & Company upped their price target on shares of Envista from $20.00 to $21.00 and gave the company an "equal weight" rating in a research report on Thursday, February 6th. Leerink Partners raised Envista from an "underperform" rating to a "market perform" rating and boosted their target price for the company from $16.00 to $23.00 in a research note on Thursday, October 31st. Finally, Leerink Partnrs upgraded Envista from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, Envista presently has an average rating of "Hold" and a consensus target price of $20.21.

Envista Trading Down 2.5 %

Shares of NVST traded down $0.55 during mid-day trading on Friday, hitting $20.91. 1,423,960 shares of the company's stock traded hands, compared to its average volume of 2,148,655. The business's 50-day moving average price is $20.08 and its 200-day moving average price is $19.46. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $23.06. The firm has a market capitalization of $3.60 billion, a P/E ratio of -3.22, a PEG ratio of 1.29 and a beta of 1.34. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, sell-side analysts forecast that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.